Hints and tips:
...Its shares have lost 5 per cent this year, while the benchmark S&P 500 gained 16 per cent....
...Séverin Brizay is leaving Bank of America just 18 months after joining the bank in London....
...S&P and Moody’s, the credit rating agencies, cut PG&E to junk status last week....
...Shares in Roche are up almost 90 per cent in the past five years but down 3 per cent this year, while the S&P pharmaceuticals index is up 7 per cent....
...“From a commercial business point of view you couldn’t be in a better industry,” says Severin Schwan, chief executive of Roche....
...Severin Schwan, chief executive, repeated Roche’s $51 a share offer, valuing the US gene sequencing group at $6.7bn, saying the price was “more than adequate”....
...Severin Schwan, Roche’s chief executive, described the results as “solid”, in spite of being “heavily affected by currency headwinds.” Roche provides no profits data at the nine months stage....
...Severin Schwan, Roche’s chief executive, will announce his company’s first-half results on Thursday....
...At Roche, Franz Humer stepped down as chief executive to concentrate on his chairman’s role, with Severin Schwan taking over as CEO....
...The Swiss drugmaker said its diagnostics chief, Severin Schwan, would succeed chief executive Franz Humer next March. Deutsche Bank upgraded its price target from SFr266 to SFr282....
International Edition